Completed or ongoing clinical trials for inhibitors of the PI3K/AKT/mTOR pathway according to highest phase reached for trials including ovarian cancer patients, indication, monotherapy or combination therapy, clinical trials and publication references. This evidence concerns the gene PIK3CB and ovarian carcinoma.